Business Context and Reporting Period
Registrant: TASER International, Inc. (now associated with Axon Enterprise, Inc.); the filing predates the Axon name. This unaudited Form 10-Q covers the three and nine months ended September 30, 2011, filed November 8, 2011.
The company develops and sells electronic control devices, accessories, training and related services, as well as AXON and EVIDENCE.com video and evidence-management solutions. It operates as one reportable segment and sells through direct sales, distributors, its online store and resellers worldwide.
Financial Performance and Position
| Metric | Q3 2011 | Q3 2010 | 9M 2011 | 9M 2010 |
|---|---|---|---|---|
| Net sales | $24.4 million | $21.1 million | $68.7 million | $64.0 million |
| Gross margin | $13.1 million; 53.7% | $10.4 million; 49.4% | $37.6 million; 54.7% | $33.5 million; 52.3% |
| Operating income (loss) | $1.2 million; 5.0% | $(0.7) million; (3.4%) | $(3.7) million; (5.4%) | $(5.1) million; (8.0%) |
| Net income (loss) | $1.1 million; $0.02/share | $(2.3) million; $(0.04)/share | $(1.1) million; $(0.02)/share | $(4.2) million; $(0.07)/share |
| Cash flow from operations | Not provided for quarter | Not provided for quarter | $14.6 million | $(2.4) million |
- Q3 sales increased 15.6%, while nine-month sales increased 7.3% year over year.
- Q3 gross margin improved primarily from product and geographic mix, manufacturing leverage and lower EVIDENCE.com operating costs; the X2 trade-in program reduced Q3 gross margin by approximately 180 basis points.
- Q3 SG&A was $9.5 million, or 38.9% of sales, versus 44.7% in the prior-year quarter. Research and development was $2.4 million, or 9.7% of sales.
- Nine-month SG&A declined 6.2% to $27.9 million, and research and development declined 11.0% to $7.9 million.
- At September 30, 2011, cash and cash equivalents were $24.6 million and short-term investments were $6.2 million, for total cash, cash equivalents and investments of $30.8 million versus $42.7 million at December 31, 2010.
- Total assets were $117.2 million and total liabilities were $23.1 million. Stockholders’ equity was $94.1 million.
- The company had no debt outstanding and had a $10.0 million revolving credit facility maturing June 30, 2013. The facility was secured primarily by accounts receivable and inventory and bore interest at rates ranging from LIBOR plus 1.25% to prime.
Material Changes Versus the Prior Comparable Period
- The TASER X2 generated $3.7 million of Q3 sales and $5.1 million for the first nine months, while X26 sales declined as customers upgraded to the X2.
- Single-cartridge sales increased 48% in Q3 and 26% for the nine-month period. International sales increased to 19% of Q3 revenue from 11% and to 22% of nine-month revenue from 18%.
- Nine-month results included a $3.3 million litigation judgment expense related to the Turner case, a $1.4 million impairment charge for the abandoned Protector product line and a $0.8 million loss on disposal or write-down of surplus EVIDENCE.com equipment. These items were not present, or were substantially lower, in the prior-year period.
- Cash flow from operations improved by $17.1 million year over year, assisted by noncash charges and working-capital changes. Investing cash outflows increased to $7.8 million, including net purchases of short-term investments.
- The company repurchased approximately 5.9 million shares for approximately $24.9 million through September 30, 2011, reducing shares outstanding and contributing substantially to the decline in cash and equity.
- Inventory declined to $15.5 million from $17.8 million at year-end, but the excess and obsolete inventory reserve increased to $0.9 million from $0.4 million.
Guidance, Outlook, Risks and Unusual Items
- Management stated that available cash, expected operating cash flow and the credit facility were expected to fund operations and strategic initiatives through 2011 and 2012, including approximately $7.6 million of remaining authorized share repurchases. No formal revenue or earnings guidance was provided.
- Management estimated a full-year 2011 effective tax rate of approximately 50% before discrete adjustments. Deferred tax assets totaled approximately $22.7 million, with no valuation allowance recorded.
- The company recorded a $2.6 million liability for unrecognized tax benefits. Recognition of these benefits would favorably affect the effective tax rate, but tax authorities could reach different conclusions.
- The company reported 55 pending product-liability lawsuits, generally involving alleged wrongful death or personal injury. The Turner matter produced a $10 million jury verdict; the company accrued $3.3 million for its estimated uninsured exposure, and judgment had not yet been entered as of the filing.
- If the Turner verdict stands, management stated that 2010 policy-year product-liability insurance could be exhausted, potentially leaving other claims from that policy year without coverage for defense costs or adverse judgments.
- Key stated risks include dependence on X26 and product adoption, acceptance of X2 and EVIDENCE.com, government budgets and regulation, product liability and publicity, intellectual-property disputes, component supply, manufacturing execution, service outages or security vulnerabilities, foreign exchange and customer credit risk.
- Management reported effective disclosure controls and procedures and no material change in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Reconcile the historical TASER International filing with the requested AXON Enterprise issuer identity and confirm the applicable successor-company reporting context.
- Assess whether the Q3 return to profitability is sustainable, given the nine-month operating loss and the effect of tax adjustments and unusual charges.
- Evaluate X2 adoption, X26 replacement trends, cartridge demand and the still-small AXON/EVIDENCE.com revenue contribution.
- Review the Turner verdict, insurance coverage, the accrued $3.3 million exposure and the potential effect of other product-liability claims.
- Verify liquidity after the $24.9 million share repurchase, including the remaining buyback authorization and availability of the undrawn credit facility.
- Monitor inventory reserves, deferred tax-asset realizability, unrecognized tax benefits and the company’s ability to sustain operating cash flow.